Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;5(3):547-52.
doi: 10.2147/tcrm.s5176. Epub 2009 Jul 12.

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Seyed Ali Sadjadi  1 , James I McMillan, Navin Jaipaul, Patricia Blakely, Su Su Hline
Affiliations

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Seyed Ali Sadjadi et al. Ther Clin Risk Manag. 2009 Jun.

Abstract

Background and objectives: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are increasingly used in a variety of settings including heart failure, renal failure, arterial hypertension, and diabetic nephropathy. The objective of this study was to investigate the prevalence of hyperkalemia with ACEI and ARB use, in a population of the United States veterans. DESIGN, SETTINGS, MATERIAL, AND MEASUREMENTS: Retrospective observational cohort study of 1163 patients on ACEIs and 1168 patients on ARBs in a single Veterans Affairs Medical Center. Electronic medical records were reviewed over a 12-month period with data collected on various demographic, laboratory, comorbidity, and medication related variables.

Results: Hyperkalemia (>5 mEq/L) was observed in 20.4% of patients on ACEIs and 31.0% on ARBs. Severe hyperkalemia (6 mEq/L or higher), was observed in 0.8% of ACEI and 2.8% of ARB users. In univariate logistic regression analyses, diabetes mellitus; serum glucose, total carbon dioxide content, creatinine, and estimated glomerular filtration rate (GFR) were significantly associated with hyperkalemia. ARB use, when compared to ACEI, was associated with a 42% increase in odds of hyperkalemia (odds ratio [OR] = 1.42; p = 0.001) in a model including adjustment for GFR and a 56% increase in odds of hyperkalemia (OR = 1.56; p < 0.001) in a model including adjustment for serum creatinine.

Conclusions: Hyperkalemia, associated with the use of ACEIs and ARBs, is usually mild and severe hyperkalemia is rare. Hyperkalemia is more common with ARBs than ACEIs. ARB use, when compared to ACEI use, may significantly and independently be associated with increased odds of hyperkalemia.

Keywords: angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; hyperkalemia.

PubMed Disclaimer

References

    1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–2018. - PubMed
    1. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure: Results from the Atlas trial. Arch Intern Med. 2001;161(2):165–171. - PubMed
    1. Cohn JN, Tognoni G Valsartan Heart Failure Trial Investigators. Randomized trial of the angiotensin receptor blocker, valsartan, in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675. - PubMed
    1. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors. Am Heart J. 2000;139:609–617. - PubMed
    1. Blake J, Deverux RV. Differential effects of direct antagonism of AII receptor blockers compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failure. Congestive Heart Fail. 2000;6:193–196. - PubMed